

Figure S1. UV-visible absorbance spectroscopy of ZnO-NPs.




Figure S2. DSC-TGA thermogram of ZnO-NPs.




Figure S3. FTIR spectrum of synthesized ZnO-NPs.




Figure S4. X-ray diffraction of synthesized ZnO-NPs.

Table S1: Stability of ZnO-NPs prepared under different Temperature and PVP concentration, results are average of three independent experiments, each involved a triplicate

PVP concentration- Day of measurement after preparation	*Preparation Condition		
	Particle Size (Dnm \pm SD)	Polydispersity Index (PDI) \pm SD	Zeta Potential (mV \pm SD)
3% w/v – Day 0	361.7 \pm 2.08	0.302 \pm 0.008	-18.2 \pm 0.14
3% w/v – Day 1	378.7 \pm 2.25	0.323 \pm 0.03	-14.93 \pm 0.5
3% w/v – Day 2	445.3 \pm 13.5	0.37 \pm 0.043	-11.6 \pm 0.11
3% w/v – Day 3	587.4 \pm 46	0.37 \pm 0.019	-7.4 \pm 0.25
10% w/v - Day 0	349.6 \pm 11	0.311 \pm 0.006	-10.6 \pm 0.2
10% w/v - Day 1	358 \pm 14.3	0.345 \pm 0.045	-13.17 \pm 0.153
10% w/v - Day 2	503 \pm 6	0.29 \pm 0.025	-13.6 \pm 0.47
10% w/v - Day 3	501.6 \pm 4.56	0.288 \pm 0.025	-13.63 \pm 0.47
*Preparation Condition; pH=8, Temperature = 70°C, RPM = 1500			

Table S2: Antimicrobial susceptibility profile of <i>S. aureus</i> ATCC 12600	
Antibiotics	Susceptibility
Gentamicin (GN)	S
Tobramycin (TOB)	S
Amikacin (AK)	S
Oxacillin (OXA)	S
Amoxicillin/clavulanate (AMC)	S
Piperacillin (PRL)	S
Cefotaxime (CTX)	R
Ceftriaxone (CRO)	S
Imipenem (IMP)	R
Meropenem (MEM)	R
Ciprofloxacin (CIP)	S
Levofloxacin (LEV)	S
Vancomycin (VA)	S

Table S3: Antimicrobial susceptibility profile of MRSA ATCC 25923	
Antibiotics	Susceptibility
Gentamicin (GN)	R
Tobramycin (TOB)	R
Amikacin (AK)	R
Oxacillin (OXA)	R
Amoxicillin/clavulanate (AMC)	R
Piperacillin (PRL)	S
Cefotaxime (CTX)	R
Ceftriaxone (CRO)	R
Cefoxitin (FOX)	S
Imipenem (IMP)	R
Meropenem (MEM)	R
Ciprofloxacin (CIP)	R
Levofloxacin (LEV)	S
Vancomycin (VA)	S

Table S4: Antimicrobial susceptibility profile of <i>K. pneumoniae</i> ATCC 10031	
Antibiotics	Susceptibility
Gentamicin (GN)	S
Tobramycin (TOB)	S
Amikacin (AK)	S
Amoxicillin/clavulanate (AMC)	R
Piperacillin (PRL)	S
Cefotaxime (CTX)	R
Ceftriaxone (CRO)	R
Imipenem (IMP)	S
Meropenem (MEM)	S
Ciprofloxacin (CIP)	R
Levofloxacin (LEV)	S

Table S5: Antimicrobial susceptibility profile of <i>Acinetobacter baumannii</i> ATCC 15308	
Antibiotics	Susceptibility
Gentamicin (GN)	R
Tobramycin (TOB)	S
Amikacin (AK)	S
Amoxicillin/clavulanate (AMC)	R
Piperacillin (PRL)	S
Cefotaxime (CTX)	R
Ceftriaxone (CRO)	S
Imipenem (IMP)	R
Meropenem (MEM)	R
Ciprofloxacin (CIP)	R
Levofloxacin (LEV)	S